Brolucizumab Treatment for Patients with Polypoidal Choroidal Vasculopathy

Purpose: To evaluate treatment outcomes of brolucizumab (BRZ) in patients with polypoidal choroidal vasculopathy (PCV), including both treatment-naive and previously treated patients.Methods: This retrospective observational study included PCV patients followed for up to 12 months after their first BRZ injection.Patients underwent the treat-and-extend or pro re nata regimen throughout the follow-up, assessing visual acuity (VA), central subfoveal thickness, subfoveal choroidal thickness, and polyp height via optical coherence tomography at each visit.The presence of intraretinal fluid or subretinal fluid, treatment intervals at the last follow-up, and intraocular inflammation (IOI) were also evaluated.Results: Ninety-two eyes (20 treatment-nave and 72 previously treated) were included.Treatment-naive patients exhibited significant improvements in both VA and anatomical outcomes, while previously treated patients primarily showed anatomical improvements with unchanged VA.In the switching group, 61.1% of patients extended their treatment interval by more than two weeks, with 36% achieving intervals longer than 12 weeks.Nine cases (9.8%) of IOI occurred, all in the switching group.Conclusions: BRZ effectively treated both treatment-naive and previously treated PCV patients, with naive patients showing superior visual outcomes.The potential for extended treatment intervals in previously treated patients suggests BRZ as a valuable option for treatment-resistant PCV.